Ursodeoxycholic acid in patients with ulcerative colitis and primary sclerosing cholangitis for prevention of colon cancer: A meta-analysis

被引：25

作者：

Ashraf I. ^{[1
]}

Choudhary A. ^{[1
]}

Arif M. ^{[1
]}

Matteson M.L. ^{[1
]}

Hammad H.T. ^{[1
]}

Puli S.R. ^{[2
]}

Bechtold M.L. ^{[1
]}

机构：

[1] Division of Gastroenterology and Hepatology, CE405, DC 043.00, University of Missouri Health Sciences Center, Columbia, MO 65212, Five Hospital Drive

[2] OSF MG Gastroenterology, Peoria, IL 61604

来源：

Indian Journal of Gastroenterology | 2012年 / 31卷 / 2期

关键词：

Chemoprevention; Colorectal cancer; Primary sclerosing cholangitis; Ulcerative colitis; Ursodeoxycholic acid; Ursodiol;

D O I：

10.1007/s12664-012-0175-3

中图分类号：

学科分类号：

摘要：

Purpose/Aim: Colon cancer risk is high in patients with ulcerative colitis (UC) and primary sclerosing cholangitis (PSC). Ursodeoxycholic acid has been shown to have some promise as a chemopreventive agent. A meta-analysis was performed to compare the efficacy of ursodeoxycholic acid in the prevention of colonic neoplasia in patients with UC and PSC. Methods: Multiple databases were searched (January 2011). Studies examining the use of ursodeoxycholic acid vs. no ursodeoxycholic acid or placebo in adult patients with UC and PSC were included. Data were extracted in standard forms by two independent reviewers. Meta-analysis for the effect of ursodeoxycholic acid was performed by calculating pooled estimates of adenoma or colon cancer formation by odds ratio (OR) with random effects model. Heterogeneity was assessed by calculating the I 2 measure of inconsistency. RevMan 5 was utilized for statistical analysis. Results: Four studies (n = 281) met the inclusion criteria. The studies were of adequate quality. Ursodeoxycholic acid demonstrated no overall improvement in adenoma (OR 0.53; 95 % CI: 0.19-1.48, p = 0.23) or colon cancer occurrence (OR 0.50; 95 % CI: 0.18-1.43, p = 0.20) as compared to no ursodeoxycholic acid or placebo in patients with UC and PSC. Conclusion: Ursodeoxycholic acid use in patients with UC and PSC does not appear to decrease the risk of adenomas or colon cancer. © 2012 Indian Society of Gastroenterology.

引用

页码：69 / 74

页数：5

共 43 条

[1]

Gyde S.N., Prior P., Allan R.N., Et al., Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centers, Gut, 29, pp. 206-207, (1988)

[2]

Lennard-Jones J.E., Cancer risk in ulcerative colitis: surveillance or surgery, Br J Surg, 72, SUPPL., (1985)

[3]

Collins Jr. R.H., Feldman M., Fordtran J.S., Colon cancer, dysplasia, and surveillance in patients with ulcerative colitis. A critical review, N Eng J Med, 316, pp. 1654-1658, (1987)

[4]

Ekbom A., Helmick C., Zack M., Adami H.O., Ulcerative colitis and colorectal cancer. A population-based study, N Engl J Med, 323, pp. 1228-1233, (1990)

[5]

Sugita A., Sachar D.B., Bodian C., Ribeiro M.B., Aufses Jr. A.H., Greenstein A.J., Colorectal cancer in ulcerative colitis. Influence of anatomical extent and age at onset on colitis-cancer interval, Gut, 32, pp. 167-169, (1991)

[6]

Broome U., Lindberg G., Lofberg R., Primary sclerosing cholangitis in ulcerative colitis-a risk factor for the development of dysplasia and DNA aneuploidy?, Gastroenterology, 102, pp. 1877-1880, (1992)

[7]

Lee Y.M., Kaplan M.M., Primary sclerosing cholangitis, N Engl J Med, 332, pp. 924-933, (1995)

[8]

Soetikno R.M., Lin O.S., Heidenreich P.A., Young H.S., Blackstone M.O., Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis, Gastrointest Endosc, 56, pp. 48-54, (2002)

[9]

Reddy B.S., Wynder E.L., Metabolic epidemiology of colon cancer. Fecal bile acids and neutral sterols in colon cancer patients and patients with adenomatous polyps, Cancer, 39, pp. 2533-2539, (1977)

[10]

Moorehead R.J., Campbell G.R., Donaldson J.D., McKelvey S.T., Relationship between duodenal bile acids and colorectal neoplasia, Gut, 28, pp. 1454-1459, (1987)

← 1 2 3 4 5 →